Results of Operations and Financial Condition
Show detailsHide details
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
Eloxx Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company developing small-molecule drugs that coax the body's protein-building machinery to "read through" genetic errors called nonsense mutations, which cause rare diseases like Alport syndrome. Its lead investigational drug, exaluren, aims to restore full-length functional proteins in patients with these conditions. Founded in 2013 by two scientists, the company went public in 2017 through a reverse merger with Sevion Therapeutics, and its name echoes the "ELX" prefix of its drug compounds.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
3.02 Unregistered Sales of Equity Securities · 3.03 Material Modification to Rights of Security Holders · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · 9.01 Financial Statements and Exhibits
5.07 Submission of Matters to a Vote of Security Holders
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 9.01 Financial Statements and Exhibits
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
1.01 Entry into a Material Definitive Agreement